Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Apatinib + SOX in AFP+ Gastric Cancer
NCT06973330Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab, Rivoceranib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Anhui Provincial Tumor Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sintilimabRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06973330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973330.